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Tumor necrosis factor- inhibition reduces CXCL-8
levels but fails to prevent fibrin generation and does
not improve outcome in a rabbit model of endotoxic
shock
PABLO RODRIGUEZ-WILHELMI, RAMON MONTES, AKIHIRO MATSUKAWA, HIDEO NARIUCHI,
VERONICA HURTADO, MARTA MONTES, JOSE HERMIDA, and EDUARDO ROCHA
PAMPLONA, SPAIN, and KUMAMOTO and TOKYO, JAPAN
The effects of a monoclonal antibody (mAb) to tumor necrosis factor- (TNF-) were
examined in a rabbit model of endotoxic shock. Intravenous administration of
lipopolysaccharide (100 g/kg/hr) for 6 hours (n  11) increased TNF- levels.
Fibrinogen was partially consumed, and fibrin deposits were seen in kidney and
lungs at 24 hours. Mortality at 24 hours was 64%. Levels of interleukin-8 (aka CXCL-8)
were notably increased. Mean arterial pressure (MAP) and leukocyte counts de-
creased, whereas creatinine levels were enhanced. The anti-TNF-mAb (20 mg/kg
i.v. bolus  5 mg/kg/h i.v. for the first 90 minutes) (n  10) efficiently inhibited the
TNF-activity. Rabbits exhibited lower CXCL-8 levels; MAP improved, the decrease in
leukocyte counts was partially prevented and creatinine levels were lower, but
fibrinogen, fibrin deposits in kidneys and lungs and mortality, 55%, were similar to
the LPS group. Rabbits that did not survive exhibited lower fibrinogen levels, more
fibrin in kidneys and lungs and higher CXCL-8 and creatinine levels than survivors,
while there were no differences in TNF-, MAP and leukocytes. Thus, the inhibition of
TNF-, although beneficial through lowering CXCL-8 levels, is not enough to im-
prove the outcome, which could be partly due to the inability to prevent the fibrin
deposits formation in kidneys and lungs. (J Lab Clin Med 2003;141:257-64)
Abbreviations: CXCL-8  interleukin-8; EDTA  ethylenediaminetetraacetate; IL  interleukin;
LPS  lipopolysaccharide; MAP  mean arterial pressure; MIP-2  macrophage inflammatory
protein-2; mAb  monoclonal antibody; NO  nitric oxide; NOx  NO2 and NO3-; SEM 
standard error of the mean; TNF-  tumor necrosis factor-
S epsis is caused by the immune response of a hostto infectious agents. It is characterized by sys-temic inflammation and activation of coagula-
tion. Sepsis can evolve to septic shock, causing hypo-
tension, coagulopathy, and multiple organ failure.1,2
Endotoxin — LPS of the outer membrane of Gram-
negative bacteria — plays a central role in septic shock.
It triggers a set of inflammatory reactions that lead to
the generation of a variety of mediators that orchestrate
the pathologic response during endotoxic shock
through such mechanisms as lipid peroxidation, NO
overproduction, and antioxidant depletion, which lead
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to hypotension and tissue damage; or through the in-
duction of a hemostatic imbalance, which leads to the
generation of fibrin and thrombi in the capillaries of
various organs and subsequent disseminated intravas-
cular coagulation.1-5 Most of these mechanisms are
initiated by cytokines. Among them, TNF- sets a
cascade of inflammatory reactions in motion, leading to
the generation of a variety of mediators that orchestrate
many pathologic responses during endotoxic shock.1-3
Therapeutic intervention directing TNF- should pre-
vent the action of those TNF-–dependent mediators in
the propagation of the inflammatory cascade.6
CXC chemokine is a large subfamily of chemokines
that attract and activate neutrophils.7 IL-8 (CXCL8)
belongs to the CXC chemokine subfamily and has been
detected in human endotoxemia.8-11 Many CXC che-
mokines are believed to be involved in the pathogenesis
of endotoxic shock.12,13 CXCL-8 can be induced by
LPS in a TNF--dependent manner;14-18 however, its
relationship with TNF- during endotoxic shock re-
mains unclear.
In this study, we infused doses of LPS large enough
to induce endotoxic shock into rabbits, along with a
mAb raised against rabbit TNF-19 that is able to neutral-
ize rabbit TNF- activity in vivo.19,20 Although CXCL-8
levels were shown to be reduced by TNF-, the anti–
TNF- mAb was not able to ameliorate fibrin deposi-
tion in kidneys and lungs, which may partly explain the
failure of this treatment to improve outcome.
METHODS
Experimental model and treatment groups. Male New
Zealand white rabbits (2.8-3.5 kg) were anesthetized by
means of intramuscular injection of 30 mg/kg ketamine
hydrochloride and 0.002 mg/kg xylazine hydrochlo-
ride. Ketamine hydrochloride boosters were given as
necessary throughout the experiment. To induce severe
endotoxemia, we infused rabbits with LPS (100 g/
kg/hr in 60 mL of saline solution, 10 mL/hr) for 6 hours
through the marginal ear vein. The rabbits were divided
into the following groups: (1) the LPS group (n  11),
in which LPS was administered without additional
treatment; (2) A group (n  10) given LPS plus mAb
directed against rabbit TNF- (murine origin, IgG1)19
through the opposite marginal ear vein in a bolus of 20
mg/kg before the start of the experiment, followed by a
5 mg/kg/hr infusion for the first 90 minutes of the LPS
challenge; additional control groups consisting of (3) 5
rabbits given saline solution; (4) 3 rabbits given saline
solution plus mAb against TNF-; and (5) 3 rabbits
given LPS plus nonspecific P3X63Ag8 mAb (murine
origin, IgG1).21 Blood was drawn from the femoral
artery before the start of the experiment and 2, 4, and 6
hours afterward. We studied mortality at 24 hours.
Surviving rabbits were killed with intravenous injec-
tions of 60 mg/kg pentobarbital (Nembutal; Abbott
Laboratories, Abbott Park, Ill), after which kidneys and
lungs were extracted for histologic analysis. Mortality
could not be studied in one mAb-treated rabbit because
the animal died as a result of deficient artery ligation
once the 6-hour LPS challenge was over.
Measurements. We quantified TNF- activity in se-
rum using a bioassay based on the cytotoxic effect of
TNF- on the neoplastic murine fibroblast–derived line
L929 (ECACC, Salisbury, UK).22 TNF- activity was
considered to be the inverse of the serum dilution
necessary to achieve 50% lysis of the L929 cells. A
recombinant human TNF- (Genzyme, Cambridge,
Mass) was used as a standard.
The Clauss method23 was used to measure fibrinogen
levels. Kidneys and lungs were removed 24 hours after
the start of the experiment. Sections were fixed in
formalin, embedded in paraffin, stained with Masson’s
trichrome, and analyzed by a pathologist blinded to the
experimental groups. In the analysis of the presence of
fibrin in kidneys and lungs, severity scores described
elsewhere were used. In brief, kidney sections were
scored on a scale of 0 to 4 as previously described24: 0,
no fibrin; 1, partial fibrin deposits in some glomeruli; 2,
partial deposits in all glomeruli; 3, large quantities of
fibrin in all glomeruli; 4, fibrin thrombi in glomerular
capillaries and in noncapillary vessels. Ten fields were
examined for each tissue section, after which the aver-
age value was calculated. A 0-4 scale was also designed
for lung sections.25 Twenty fields were examined and
the fields found to contain intravascular fibrin were
counted. Lungs in which 20 out of 20 fields were
positive were scored 4; lungs in which none of the
fields was positive were scored 0.
To measure CXCL-8 and IL-1 levels in rabbit se-
rum, we used two sandwich enzyme-linked immu-
nosorbent assays.14,26 In brief, plates were coated with
affinity-purified goat anti–rabbit CXCL-8 IgG or puri-
fied goat anti–rabbit IL-1 IgG, and detection was
performed with the use of biotinylated goat anti–rabbit
CXCL-8 IgG or biotinylated goat anti–rabbit IL-1
IgG. Processing was performed in both assays with the
use of avidin-biotin-peroxidase complex (Vector Lab-
oratories, Burlingame, Calif) and o-phenylenediamine.
The lower detection limits were 30 and 10 pg/mL in the
CXCL-8 and IL-1 assay, respectively. Both tests were
specific, and no cross-reaction with other cytokines/
chemokines occurred.
We monitored blood pressure with an arterial cathe-
ter connected to a pressure transducer (Siemens, Mu-
nich, Germany). MAP was determined electronically
with the blood-pressure signal (HP1290C; Hewlett-
Packard, Palo Alto, Calif). MAP was recorded imme-
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diately before the start of the LPS challenge and 2, 4,
and 6 hours afterward. MAP value was calculated as
follows: MAP (mm Hg)  [2  diastolic arterial pres-
sure (mm Hg)  systolic arterial pressure (mm Hg)]/3.
The value obtained before the start of the experiment
was discarded because it was influenced by the anes-
thesia needed to carry out artery and vein cannulation.
Serum creatinine levels were measured with a direct
colorimetric method.27
Peripheral leukocytes were quantified in blood drawn
into tubes containing K3-EDTA with a Counter STKS
automatic analyzer (Coulter Corp, Hialeah, Fla).
The serum levels of NOx were determined with the
use of a commercially available kit (Cayman; Alexis
Corp, San Diego, Calif) based on the Griess method.28
Statistical analysis. So that we might normalize the
CXCL-8 and IL-1 data, we subtracted the baseline
value for each rabbit from each value. Fibrinogen,
MAP, creatinine, leukocyte count, and NOx data were
expressed as percentages with respect to baseline val-
ues.
Student’s t test or the Mann-Whitney U test was
applied to compare the LPS group with the anti–TNF-
–treated group and to compare rabbits that survived
24 hours with those that did not. We calculated the
Pearson or Spearman correlation coefficient to analyze
the association between variables.
Results are expressed as mean  SEM.
RESULTS
TNF- activity. When all the rabbits included in the
study were taken into account, baseline TNF- activity
was 0.019  0.003 U/L (n  32). Anti–TNF- mAb
treatment efficiently inhibited increased serum TNF-
activity after the LPS challenge: TNF- activity peaked
at 2 hours in the LPS group (11.1  2.9 U/L), and no
increase was detected in the sera of the anti–TNF-–
treated rabbits (Fig 1, A).
When mortality at 24 hours was analyzed, no differ-
ences were detected between the LPS group and the
anti–TNF-–treated group, in spite of TNF- inhibi-
tion: 7 of 11 rabbits (63.6%) died in the LPS group,
compared with 5 of 9 (55.5%) in the anti–TNF-–
treated group. When rabbits were grouped according to
whether they survived 24 hours, regardless of treat-
ment, serum TNF- activity in the nonsurvivor animals
was not significantly different from that observed in the
survivors (6.5  2.3 and 4.8  4.4 U/L at 2 hours in
nonsurvivors and survivors, respectively). Furthermore,
we detected no differences in TNF- activity between
survivors and nonsurvivors within each treatment
group (Fig 1, B).
Hemostasis. Fibrinogen levels demonstrated continu-
ous decreases in the LPS group during the 6 hours of
LPS infusion. The anti–TNF- mAb did not prevent
such a decrease; fibrinogen levels were similar to those
in the LPS group (Fig 2, A). However, fibrinogen
consumption was significantly higher in the animals
that did not survive 24 hours, regardless of treatment,
than in survivors (72.6%  4.6% vs 90.2%  2.6% at
4 hours, P .01, and 57.5% 7.5% vs 83.8% 3.7%
at 6 hours, P  .01, in nonsurvivors and survivors,
respectively; Fig 2, D).
Fibrin deposits in the kidneys were similar in the
LPS-and anti–TNF-–treated rabbits (scores of 1.80 
0.41 in the LPS group and 1.78  0.39 in the anti–
TNF-–treated group; Fig 2, B). The animals that did
not survive 24 hours exhibited renal fibrin deposits
higher than those observed in the survivor animals,
regardless of treatment (2.12 0.31 in nonsurvivors vs
1.40  0.37 in survivors; Fig 2, E). Moreover, necrotic
areas were always seen in kidneys when fibrin was
present in glomeruli and tubules.
Lung fibrin deposits were similar in the LPS-and
anti–TNF-–treated rabbits (0.31  0.05 in the LPS
group vs 0.29 0.07 in the anti–TNF-–treated group;
Fig 2, C). Again the nonsurvivor animals exhibited
more extensive lung fibrin deposits than the survivor
animals, regardless of treatment (0.40  0.05 in non-
survivors vs 0.22  0.04 in survivors, P  .05; Fig 2,
F).
CXCL-8 levels. The mean baseline CXCL-8 level for
the entire study population was 0.99  0.60 ng/mL
(n  32). Serum CXCL-8 levels increased in both
groups and peaked 2 hours after the start of the LPS
challenge. However, levels in the rabbits treated with
anti–TNF- mAb rabbits were remarkably attenuated
(183.2  24.4 vs 66.1  13.6 ng/mL at 2 hours [P 
0.01], 124.2  37.8 vs 33.2  12.2 ng/mL at 4 hours
[P  .05], and 140.5  71.2 vs 22.1  11.3 ng/mL at
6 hours [P .05] in LPS-and anti–TNF- mAb–treated
groups, respectively; Fig 3, A). Accordingly, when data
from all the LPS-challenged rabbits (n  24) were
pooled, CXCL-8 levels correlated remarkably well with
TNF- activity at their peak (2 hours): r  .613, P 
.01.
CXCL-8 levels were significantly higher in the rab-
bits that did not survive 24 hours, regardless of treat-
ment (129.2  33.4 vs 31.9  8.9 ng/mL at 4 hours
[P  0.05] and 138.0  64.5 vs 14.4  5.0 ng/mL at
6 hours [P  .05] in nonsurvivors and survivors, re-
spectively; Fig 3, C).
IL-1 levels. The baseline IL-1 level for the entire
study population was 16.5  5.2 pg/mL (n  32). We
noted a tendency for the level of IL-1 to decrease after
treatment with anti–TNF- mAb (Fig 3, B), although
this trend was not statistically significant. IL-1 levels
in nonsurvivor rabbits, regardless of treatment, were
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not significantly higher than those observed in survi-
vors (Fig 3, D), although we did note such a trend.
MAP, renal dysfunction, and peripheral leukocyte
count. MAP was significantly improved at 4 and 6
hours by treatment with anti–TNF- mAb (58.2% 
5.9% vs 74.6% 3.4% at 4 hours [P .05] and 54.2%
 4.6% vs 83.6%  3.9% at 6 hours [P  .05] in LPS
and anti–TNF- mAb–treated animals, respectively;
Fig 4, A).
Creatinine levels in the rabbits treated with anti–TNF-
mAb were significantly lower than those observed in
the LPS group at 2 and 4 hours (115.9%  3.3% vs
101.3%  4.8% at 2 hours [P  .05] and 150.7% 
6.1% vs 130.1%  7.8% at 4 hours [P  .05] in the
LPS and anti–TNF- mAb–treated groups, respective-
ly; Fig 4, B). We detected no differences at 6 hours.
The anti–TNF- mAb significantly attenuated the
decrease in leukocyte counts observed in the LPS group
(27.0%  2.5% vs 35.6%  4.1% at 4 hours [P  .05]
and 31.4%  3.0% vs 49.2%  8.3% at 6 hours [P 
.05] in the LPS and anti–TNF-–treated groups, respec-
tively; Fig 4, C).
Although MAP and leukocyte counts were similar in
survivors and nonsurvivors, regardless of treatment
Fig 1. Serum TNF- activity (U/L) at 2, 4, and 6 hours: A, in the LPS group and the anti–TNF- mAb–treated
group; B, in survivors and nonsurvivors within each group. Data expressed as mean  SEM. *P  .001 with
respect to the LPS group.
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(Fig 4, D and F), creatinine levels were significantly
higher in nonsurvivors at 6 hours (177%  19% and
133%  7% [P  .05] in nonsurvivors and survivors,
respectively; Fig 4, E).
We pooled all data from rabbits challenged with LPS
so that we might analyze the correlation between
CXCL-8 levels, MAP, and renal dysfunction. CXCL-8
levels correlated remarkably well with MAP (r –.729
at 2 hours, P .01; r –.851 at 4 hours, P .001) and
with creatinine concentration (r  .654 at 2 hours, P 
.01; r  .678 at 4 hours, P  .001; r  .729 at 6 hours,
P  .001).
NOx levels. Anti–TNF- mAb treatment did not alter
serum NOx levels, which were 109.0%  19.7%,
91.2%  6.7%, and 85.8%  6.5%, respectively, at 2,
4 and 6 hours with respect to those observed in the LPS
group. The nonsurvivor animals exhibited NOx levels
similar to those observed in the survivor animals
(116.6%  14.0%, 105.5%  2.9%, and 111.4% 
4.7% at 2, 4, and 6 hours, respectively, with respect to
survivor levels).
Control rabbits. Rabbits not challenged with LPS but
administered saline solution or saline solution plus an-
ti–TNF- mAb tolerated femoral catheter and ear vein
cannulation well and did not demonstrate alterations in
the variables included in the study (data not shown).
Rabbits given LPS plus nonspecific P3X63Ag8 mAb
demonstrated changes similar to those observed in the
LPS group (data not shown).
DISCUSSION
The important role played by TNF- in sepsis is
unquestionable.1-3 However, LPS elicits a wide range
of responses that involve many different mediators. For
this reason, in spite of the efficiency of the anti–TNF-
mAb in inhibiting TNF- activity, the inability of this
treatment to improve outcome in our model of severe
sepsis should not be surprising. The inhibition of
TNF- activity notably prevented CXCL-8 and, to a
lesser extent, IL-1 production and improved MAP,
leukocyte count, and renal dysfunction during the LPS-
infusion period. However, the similar mortality rates in
control and treated rabbits suggest the existence of
LPS-induced mechanisms that influenced outcome and
were not controlled by the anti–TNF- mAb. One
important contributor to multiorgan failure in sepsis is
hemostatic imbalance leading to disseminated intravas-
cular coagulation. The inability of the anti–TNF-
Fig 2. Fibrinogen levels at 2, 4, and 6 hours: in the LPS and anti–TNF- mAb–treated groups (A); in survivors
and nonsurvivors (D). Fibrin deposits in kidneys (B) and lungs (C) in LPS and anti–TNF- mAb–treated group.
Kidneys (E) and lungs (F) in the survivors and nonsurvivors. Data expressed as mean SEM. *P .05. **P
.01 with respect to survivors.
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mAb to prevent the consumption of fibrinogen and the
subsequent LPS-induced generation of fibrin does not
support the notion that TNF- plays a pivotal role in
triggering coagulation in sepsis2,29 and could partly
explain the failure of this treatment to prevent death;
fibrin deposits in kidneys and lungs were more exten-
sive in rabbits that did not survive the experiment.
IL-1 seems to play a more preponderantly prothrom-
botic role in sepsis.29,30 Nevertheless, factors other than
TNF-/IL-1 that were not corrected by the treatment
must also be involved in the generation of fibrin; renal
and pulmonary fibrin deposits were similar in LPS-
treated and mAb-treated rabbits in spite of the TNF-
and IL-1 decreases after treatment.
CXCL-8 increased in serum after LPS infusion,
peaking at 2 hours, when TNF- activity had also
reached its peak. Anti–TNF- mAb treatment effi-
ciently decreased serum levels of CXCL-8. Because
levels of TNF- and CXCL-8 correlated to a high
degree during the experiment, we conclude that the
up-regulation of CXCL-8 in severe endotoxemia is
driven by TNF-, as is the case in other LPS-based in
vivo models.16,18,31 However, a down-regulatory effect
of some CXC chemokines on TNF- has been de-
scribed32; a down-regulation of the TNF- activity by
CXCL-8 could also contribute to this high correlation.
Even a regulation of both TNF- and CXCL-8 by some
other common mediator cannot be ruled out.
It should be noted that CXCL-8 levels were signifi-
cantly higher in the rabbits that did not survive 24 hours
than in survivors, whereas no such difference was
found with regard to TNF- activity. The involvement
of CXCL-8 in sepsis is indubitable 33-35: CXCL-8 is a
potent contributor to neutrophil infiltration and neutro-
phil-mediated tissue injury in a variety of LPS-induced
models of inflammation.14-18 However, some of the
Fig 3. Serum CXCL-8 (ng/mL) and IL-1 (pg/mL) increments at 2, 4, and 6 hours. CXCL-8 (A) and IL-1
(B) in the LPS and anti–TNF- mAb–treated groups. CXCL-8 (C) and IL-1 (D) in survivors and nonsurvivors.
Data expressed as mean  SEM. *P  .05. **P  .01 with respect to the LPS group (A) or the survivor group
(C).
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actions induced by CXCL-8 in sepsis remain unclear.
We found an important correlation of serum CXCL-8
levels with MAP and renal dysfunction. A direct rela-
tionship between CXCL-8 and MAP/creatinine cannot
be inferred from correlation analysis. However, it is
tempting to speculate that CXCL-8 is involved in hy-
potension and the subsequent kidney failure in severe
sepsis; a recent study by Matsukawa et al in a sepsis
model showed that therapeutic control of the levels of
two CXC chemokines, MIP-2 and KC, improved kid-
ney function without notably changing renal neutrophil
influx.36 The fact that renal injury in sepsis can be at
least partly caused by renal hypoperfusion rather than
inflammation would support this hypothesis.37 Never-
theless, the mechanism by which CXCL-8 may hamper
hemodynamics in endotoxemia is unclear, and further
work will be required to test this hypothesis.
Finally, the finding that the NOx values observed in
the LPS and anti–TNF- mAb–treated groups were
similar suggests that TNF- is not the only cytokine
resposible for NO overproduction in sepsis. Neverthe-
less, the fact that NOx levels were also similar among
survivors and nonsurvivors does not support a key role
for NO in the outcome with this model.
We thus conclude that successful inhibition of
TNF- activity was not enough to prevent fatality in
this rabbit model of severe sepsis. Although inhibition
of TNF- improved MAP, renal dysfunction, leukocyte
counts, and CXCL-8 levels, the similar mortality rates
in control and treated rabbits may have been at least
partially caused by the inability of the mAb to prevent
the fibrin deposition and subsequent tissue damage
revealed on histologic analysis. Because the range of
inflammatory mechanisms triggered by LPS is so wide,
treatments should not be limited to single targets.
We acknowledge the technical assistance of Mercedes Fernndez
and Yolanda Azcona.
REFERENCES
1. Karima R, Matsumoto S, Higashi H, Matsushima K. The molec-
ular pathogenesis of endotoxic shock and organ failure. Mol Med
Today 1999;5:123-32.
2. Levi M, ten Cate H. Disseminated intravascular coagulation.
N Engl J Med 1999;341:586-92.
3. Dinarello CA. Proinflammatory cytokines. Chest
2000;118:503-8.
4. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski
R, et al. Association between mitochondrial dysfunction and
severity and outcome of septic shock. Lancet 2002;360:219-23.
5. Esmon CT, Fukudome K, Mather T, Bode W, Regan LM,
Stearns-Kurosawa DJ, et al. Inflammation, sepsis, and coagula-
tion. Haematologica 1999;84:254-9.
6. Neumann B, Zantl N, Veihelmann A, Emmanuilidis K, Pfeffer
K, Heidecke CD, et al. Mechanisms of acute inflammatory lung
injury induced by abdominal sepsis. Int Immunol 1999;11:217-
27.
Fig 4. MAP, creatinine, and leukocyte counts (percentage of baseline value) at 2, 4, and 6 hours: MAP (A),
creatinine (B), and leukocyte counts (C) in the LPS and anti–TNF- mAb–treated groups. MAP (D), creatinine
(E), leukocyte counts (F) in survivors and nonsurvivors. Data expressed as mean SEM. *P .05 with respect
to LPS group (A, B, and C) or survivors (E).
J Lab Clin Med
Volume 141, Number 4 Rodriguez-Wilhelmi et al 263
7. Murdoch C, Finn A. Chemokine receptors and their role in
inflammation and infectious diseases. Blood 2000;95:3032-43.
8. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to
endotoxin. Immunobiology 1993;187:403-16.
9. Olszyna DP, Pajkrt D, van Deventer SJ, van der Poll T. Effect of
interleukin 10 on the release of the CXC chemokines growth
related oncogene GRO-alpha and epithelial cell-derived neutro-
phil activating peptide (ENA)-78 during human endotoxemia.
Immunol Lett 2001;78:41-4.
10. Olszyna DP, De Jonge E, Dekkers PE, van Deventer SJ, van der
Poll T. Induction of cell-associated chemokines after endotoxin
administration to healthy humans. Infect Immun
2001;69:2736-8.
11. Marie C, Fitting C, Cheval C, Losser MR, Carlet J, Payen D, et
al. Presence of high levels of leukocyte-associated interleukin-8
upon cell activation and in patients with sepsis syndrome. Infect
Immun 1997;65:865-71.
12. Kunkel SL. Through the looking glass: the diverse in vivo
activities of chemokines. J Clin Invest 1999;104:1333-4.
13. Fox-Dewhurst R, Alberts MK, Kajikawa O, Caldwell E, Johnson
III MC, Skerrett SJ, et al. Pulmonary and systemic inflammatory
responses in rabbits with gram-negative pneumonia. Am J Respir
Crit Care Med 1997;155:2030-40.
14. Matsukawa A, Yoshimura T, Miyamoto K, Ohkawara S, Yoshi-
naga M. Analysis of the inflammatory cytokine network among
TNF alpha, IL-1beta, IL-1 receptor antagonist, and IL-8 in LPS-
induced rabbit arthritis. Lab Invest 1997;76:629-38.
15. Matsukawa A, Miyazaki S, Maeda T, Tanase S, Feng L, Oh-
kawara S, et al. Production and regulation of monocyte chemoat-
tractant protein-1 in lipopolysaccharide-or monosodium urate
crystal–induced arthritis in rabbits: roles of tumor necrosis factor
alpha, interleukin-1, and interleukin-8. Lab Invest 1998;78:973-
85.
16. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. Role and
regulation of IL-8 and MCP-1 in LPS-induced uveitis in rabbits.
Exp Eye Res 1999;68:333-40.
17. Matsukawa A, Yoshimura T, Fujiwara K, Maeda T, Ohkawara S,
Yoshinaga M. Involvement of growth-related protein in lipopo-
lysaccharide-induced rabbit arthritis: cooperation between
growth-related protein and IL-8, and interrelated regulation
among TNFalpha, IL-1, IL-1 receptor antagonist, IL-8, and
growth-related protein. Lab Invest 1999;79:591-600.
18. Mo JS, Matsukawa A, Ohkawara S, Yoshinaga M. CXC chemo-
kine GRO is essential for neutrophil infiltration in LPS-induced
uveitis in rabbits. Exp Eye Res 2000;70:221-6.
19. Haranaka K, Satomi N, Sakurai A, Nariuchi H. Purification and
partial amino acid sequence of rabbit tumor necrosis factor. Int J
Cancer 1985;36:395-400.
20. Kawasaki H, Moriyama M, Ohtani Y, Naitoh M, Tanaka A,
Nariuchi H. Analysis of endotoxin fever in rabbits by using a
monoclonal antibody to tumor necrosis factor (cachectin). Infect
Immun 1989;57:3131-5.
21. Kohler G, Milstein C. Continuous cultures of fused cells secret-
ing antibody of predefined specificity. Nature 1975;256:495-7.
22. Aggarwal BB, Kohr WH. Human tumour necrosis factor. Meth-
ods Enzymol 1985;116:448-56.
23. Mackie J, Lawrie AS, Kitchen S, Gaffney PJ, Howarth D, Lowe
GD, et al. A performance evaluation of commercial fibrinogen
reference preparations and assays for Clauss and PT-derived
fibrinogen. Thromb Haemost 2002;87:997-1005.
24. Montes R, Declerck PJ, Calvo A, Montes M, Hermida J, Mun˜oz
MC, et al. Prevention of renal fibrin deposition in endotoxin-
induced DIC through inhibition of PAI-1. Thromb Haemost
2000;84:65-70.
25. Montes R, Rodrı´guez-Wilhelmi P, Hurtado V, Matsukawa A,
Montes M, Hermida J, et al. The endotoxin-induced plasminogen
activator inhibitor-1 increase in rabbits is not tumor necrosis
factor-dependent and can occur in the absence of interleukin-1.
Thromb Haemost 2002;88:639-43.
26. Matsukawa A, Ohkawara S, Maeda T, Takagi K, Yoshinaga M.
Production of IL-1 and IL-1 receptor antagonist and the patho-
logical significance in lipopolysaccharide-induced arthritis in
rabbits. Clin Exp Immunol 1993;93:206-11.
27. Heinegard D, Tiderstrom G. Determination of serum creatinine
by a direct colorimetric method. Clin Chim Acta 1973;43:305-
10.
28. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS,
Tannenbaum SR. Analysis of nitrate, nitrite and [15N]nitrate in
biological fluids. Anal Biochem 1982;126:131-8.
29. ten Cate H, Timmerman JJ, Levi M. The pathophysiology of
disseminated intravascular coagulation. Thromb Haemost 1999;
82:713-7.
30. ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer
SJ. Cytokines: triggers of clinical thrombotic disease. Thromb
Haemost 1997;78:415-9.
31. van Deventer SJ, Hart M, van der Poll T, Hack CE, Aarden LA.
Endotoxin and tumor necrosis factor-alpha–induced interleu-
kin-8 release in humans. J Infect Dis 1993;167:461-4.
32. Zisman DA, Kunkel SL, Strieter RM, Tsai WC, Bucknell K,
Wilkowski J, et al. MCP-1 protects mice in lethal endotoxemia.
J Clin Invest 1997;99:2832-6.
33. Mukaida N. Interleukin-8: an expanding universe beyond neu-
trophil chemotaxis and activation. Int J Hematol 2000;72:391-8.
34. Lin KJ, Lin J, Hanasawa K, Tani T, Kodama M. Interleukin-8 as
a predictor of the severity of bacteremia and infectious disease.
Shock 2000;14:95-100.
35. Matsumoto T, Yokoi K, Mukaida N, Harada A, Yamashita J,
Watanabe Y, et al. Pivotal role of interleukin-8 in the acute
respiratory distress syndrome and cerebral reperfusion injury.
J Leukoc Biol 1997;62:581-7.
36. Matsukawa A, Kaplan MH, Hogaboam CM, Lukacs NW,
Kunkel SL. Pivotal role of signal transducer and activator of
transcription (Stat)4 and Stat6 in the innate immune response
during sepsis. J Exp Med 2001;193:679-88.
37. Groeneveld AB. Pathogenesis of acute renal failure. Nephrol
Dial Transplant 1994;9:47-51.
J Lab Clin Med
264 Rodriguez-Wilhelmi et al April 2003
